Oncopharmpod
Updates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AML
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:14:09
- Mas informaciones
Informações:
Sinopsis
Discussion of 2 important malignant hematology updates: the NEJM publication of the 1st published results of CAR-T therapy in multiple myeloma and the FDA-approval of ivosidenib in frail AML patients (with IDH1 mutations).
